Danaher Corporation (DHR)

Currency in USD
184.04
-10.50(-5.40%)
Closed·
183.80-0.24(-0.13%)
·
DHR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
183.71195.01
52 wk Range
180.03242.80
Key Statistics
Prev. Close
194.54
Open
193.95
Day's Range
183.71-195.01
52 wk Range
180.03-242.8
Volume
5.82M
Average Volume (3m)
4.29M
1-Year Change
-4.1808%
Book Value / Share
74.82
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DHR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
253.00
Upside
+37.47%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 8 consecutive years

Danaher Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Danaher Corporation SWOT Analysis


Life Sciences Leade
Danaher Corporation, a $150B market cap giant, dominates life sciences, diagnostics, and CROs sectors with robust financial health and strategic market positioning
Financial Trajectory
Analysts project steady growth for Danaher, with revenue expected to reach $27.67B by 2027 and EPS rising to $9.56, showcasing strong financial outlook
Strategic Evolution
Explore Danaher's proactive cost-saving measures and operational efficiencies, aimed at expanding margins into the mid-30s and enhancing shareholder value
Market Dynamics
Average analyst price target of $284, reflecting varied perspectives on Danaher's growth potential amid biotech recovery and ongoing challenges in China
Read full SWOT analysis

Danaher Corporation Earnings Call Summary for Q1/2026

  • Danaher Q1 2026 EPS of $2.06 beat estimates of $1.94 by 6.19%; revenue of $5.95B slightly missed $5.99B forecast by 0.67%
  • Stock rose 0.77% to $197 in premarket trading; adjusted operating margin expanded 60 bps to 30.2% through effective cost management
  • Biotechnology segment drove growth with 7% core revenue increase; overall core revenue up 0.5% YoY despite 2.5% respiratory diagnostics headwind
  • Free cash flow reached $1.1B with 105% conversion ratio; company maintained 34-year dividend payment streak with 0.82% current yield
  • Management projects continued growth in bioprocessing and life sciences; CEO cited Danaher Business System execution as key profitability driver
Last Updated: 2026-04-21, 09:22 a/m
Read Full Transcript

Compare DHR to Peers and Sector

Metrics to compare
DHR
Peers
Sector
Relationship
P/E Ratio
35.4x26.3x−0.4x
PEG Ratio
89.90−3.220.00
Price/Book
2.5x2.6x2.6x
Price / LTM Sales
5.3x2.6x3.2x
Upside (Analyst Target)
27.2%0.0%45.4%
Fair Value Upside
Unlock17.3%7.0%Unlock

Analyst Ratings

22 Buy
2 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 253.00
(+37.47% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Buy255.00+38.56%270.00MaintainApr 22, 2026
UBS
Buy250.00+35.84%270.00MaintainApr 22, 2026
Stifel
Buy260.00+41.27%-MaintainApr 22, 2026
Guggenheim
Buy235.00+27.69%275.00MaintainApr 22, 2026
Baird
Buy245.00+33.12%249.00MaintainApr 22, 2026

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.19%
Dividend Yield
0.82%
Industry Median 1.45%
Annualized payout
1.60
Paid quarterly
5-Years Growth
+12.20%
Growth Streak

Earnings

Latest Release
Apr 21, 2026
EPS / Forecast
2.06 / 1.94
Revenue / Forecast
5.95B / 5.99B
EPS Revisions
Last 90 days

DHR Income Statement

People Also Watch

63.26
FISV
0.00%
385.18
TER
+1.38%
408.68
INTU
+0.95%
200.55
CAH
-2.13%

FAQ

What Is the Danaher (DHR) Stock Price Today?

The Danaher stock price today is 184.04 USD.

What Stock Exchange Does Danaher Trade On?

Danaher is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Danaher?

The stock symbol for Danaher is "DHR."

Does Danaher Pay Dividends? What’s The Current Dividend Yield?

The Danaher dividend yield is 0.87%.

What Is the Danaher Market Cap?

As of today, Danaher market cap is 130.70B USD.

What Is Danaher's Earnings Per Share (TTM)?

The Danaher EPS (TTM) is 5.19.

When Is the Next Danaher Earnings Date?

Danaher will release its next earnings report on Jul 28, 2026.

From a Technical Analysis Perspective, Is DHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Danaher Stock Split?

Danaher has split 5 times.

How Many Employees Does Danaher Have?

Danaher has 59000 employees.

What is the current trading status of Danaher (DHR)?

As of Apr 22, 2026, Danaher (DHR) is trading at a price of 184.04 USD, with a previous close of 194.54 USD. The stock has fluctuated within a day range of 183.71 USD to 195.01 USD, while its 52-week range spans from 180.03 USD to 242.80 USD.

What Is Danaher (DHR) Price Target According to Analysts?

The average 12-month price target for Danaher is 253.00 USD, with a high estimate of 310 USD and a low estimate of 205 USD. 22 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +37.47% Upside potential.

What Is the DHR Premarket Price?

DHR's last pre-market stock price is 193.99 USD. The pre-market share volume is 1,590.00, and the stock has decreased by -0.55, or -0.28%.

What Is the DHR After Hours Price?

DHR's last after hours stock price is 183.80 USD, the stock has decreased by -0.24, or -0.13%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.